Workflow
化学制剂
icon
Search documents
泰恩康涨2.05%,成交额2.15亿元,主力资金净流入844.58万元
Xin Lang Zheng Quan· 2025-09-16 05:31
Company Overview - Taiankang Pharmaceutical Co., Ltd. is located in Shantou, Guangdong Province, established on January 22, 1999, and listed on March 29, 2022 [1] - The company's main business includes the agency operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials, as well as providing pharmaceutical technology services and technology transfer [1] - The revenue composition is as follows: pharmaceutical agency 65.16%, pharmaceutical manufacturing 31.70%, pharmaceutical technology services and technology transfer 2.97%, and others 0.17% [1] Stock Performance - As of September 16, Taiankang's stock price increased by 2.05%, reaching 38.37 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 1.86%, resulting in a total market capitalization of 16.326 billion CNY [1] - Year-to-date, the stock price has risen by 159.41%, with a 2.81% increase over the last five trading days, 7.78% over the last 20 days, and 9.79% over the last 60 days [1] Financial Performance - As of June 30, Taiankang reported a decrease in revenue to 347 million CNY for the first half of 2025, a year-on-year decline of 12.23%, and a net profit attributable to shareholders of 37.08 million CNY, down 56.75% year-on-year [2] - The number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2] Dividend Information - Since its A-share listing, Taiankang has distributed a total of 460 million CNY in dividends, with 377 million CNY distributed over the past three years [3]
艾力斯跌2.02%,成交额3.06亿元,主力资金净流出4050.27万元
Xin Lang Zheng Quan· 2025-09-16 03:06
Core Viewpoint - The stock of Ailis has experienced fluctuations, with a notable decline of 2.02% on September 16, 2023, despite a year-to-date increase of 86.01% [1] Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57% [2] - The net profit attributable to shareholders for the same period was 1.051 billion yuan, showing a year-on-year increase of 60.22% [2] Shareholder Information - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period [2] - The average number of circulating shares per shareholder was 34,578, a decrease of 3.48% [2] Dividend Distribution - Ailis has distributed a total of 653 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included notable entities such as Huaxia SSE Sci-Tech 50 ETF, which increased its holdings by 1.3199 million shares to 12.4209 million shares [3] - Hong Kong Central Clearing Limited reduced its holdings by 246,090 shares to 10.3778 million shares [3] - New institutional shareholder, China Europe Medical Health Mixed A, holds 9.1525 million shares [3]
一品红跌2.06%,成交额1.24亿元,主力资金净流出1741.82万元
Xin Lang Cai Jing· 2025-09-16 02:41
9月16日,一品红盘中下跌2.06%,截至10:13,报60.93元/股,成交1.24亿元,换手率0.48%,总市值 275.22亿元。 资金流向方面,主力资金净流出1741.82万元,特大单买入259.43万元,占比2.10%,卖出703.22万元, 占比5.68%;大单买入1980.41万元,占比16.00%,卖出3278.45万元,占比26.48%。 一品红今年以来股价涨257.15%,近5个交易日跌11.13%,近20日跌14.83%,近60日涨19.56%。 一品红所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:抗流感、医药电商、肝炎 治疗、中药、猴痘概念等。 截至8月31日,一品红股东户数2.14万,较上期增加0.49%;人均流通股19553股,较上期减少0.49%。 2025年1月-6月,一品红实现营业收入5.84亿元,同比减少36.02%;归母净利润-7354.22万元,同比减少 258.30%。 分红方面,一品红A股上市后累计派现3.35亿元。近三年,累计派现1.51亿元。 机构持仓方面,截止2025年6月30日,一品红十大流通股东中,易方达医疗保健行业混合A(110023) ...
海思科跌2.03%,成交额1.03亿元,主力资金净流出267.49万元
Xin Lang Zheng Quan· 2025-09-15 05:16
Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]
9月15日早间重要公告一览
Xi Niu Cai Jing· 2025-09-15 05:03
Group 1 - Dashi Intelligent signed a contract worth 23.86 million yuan for the Xiaomi Wuhan Phase II smart project, providing a comprehensive smart space solution [1] - ST Tian Sheng's subsidiary passed the consistency evaluation for sodium bicarbonate injection, used for treating metabolic acidosis and certain drug poisonings [1] - Yongyue Technology's actual controller Chen Xiang was released on bail due to allegations of information disclosure violations, while the company's operations remain normal [2] Group 2 - Jushen Co. experienced a stock price fluctuation with a cumulative increase of over 20% over three trading days, while also planning to reduce repurchased shares [2][3] - Shanghai Airport reported a 6.9% year-on-year increase in passenger throughput at Pudong International Airport, totaling 7.9471 million passengers in August [3][4] - Jianlong Micro-Nano announced plans for shareholders to reduce up to 3% of company shares due to fund expiration and exit arrangements [5][6] Group 3 - Yunyong Technology's shareholders plan to reduce up to 2.99% of company shares due to personal funding needs [6] - Zitian Tui's stock entered a delisting arrangement period, expected to last 15 trading days [7] - Pruis's shareholders plan to reduce up to 3% of company shares for personal funding needs [9] Group 4 - Dayilong's shareholders plan to reduce up to 3% of company shares for personal financial arrangements [10] - Yihua New Materials' shareholders plan to reduce up to 1% of company shares for personal funding needs [12] - Huibo Yuntong's controlling shareholder's affiliates plan to acquire a controlling stake in Baode Computer [13] Group 5 - Wanda Information's shareholders plan to reduce up to 3% of company shares for operational needs [14] - Jiafa Education's shareholders plan to reduce up to 3% of company shares for personal funding needs [15] - Guangkang Biochemical's shareholders plan to reduce up to 1.8% of company shares for personal funding needs [16] Group 6 - Yingxin Development's shareholders plan to reduce up to 0.67% of company shares due to bankruptcy asset disposal [18] - Weiye Co.'s shareholders plan to reduce a total of up to 2% of company shares [19] - Kelin Electric plans to raise up to 1.5 billion yuan through a private placement to supplement working capital [20]
复星医药涨2.03%,成交额8.01亿元,主力资金净流入2087.90万元
Xin Lang Cai Jing· 2025-09-15 03:16
Company Overview - Fosun Pharma's stock price increased by 2.03% on September 15, reaching 32.16 CNY per share, with a trading volume of 8.01 billion CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 858.81 billion CNY [1] - The company was established on May 31, 1995, and listed on August 7, 1998, with its main business focusing on drug manufacturing and research, covering medical devices, medical services, and pharmaceutical distribution and retail [1] Financial Performance - For the first half of 2025, Fosun Pharma reported a revenue of 19.514 billion CNY, a year-on-year decrease of 4.63%, while the net profit attributable to shareholders increased by 38.96% to 1.702 billion CNY [2] - The company has distributed a total of 12.593 billion CNY in dividends since its A-share listing, with 2.691 billion CNY distributed over the past three years [2] Stockholder Information - As of June 30, 2025, the number of shareholders decreased by 4.37% to 230,000, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 75.8807 million shares, an increase of 11.1938 million shares from the previous period [3]
海辰药业跌2.01%,成交额4.06亿元,主力资金净流出1877.84万元
Xin Lang Zheng Quan· 2025-09-15 02:56
资料显示,南京海辰药业股份有限公司位于江苏省南京经济技术开发区恒发路1号,成立日期2003年1月 15日,上市日期2017年1月12日,公司主营业务涉及化学制剂、原料药及中间体的研发、生产、销售。 主营业务收入构成为:心脑血管类87.12%,抗生素类5.69%,原料药及中间体1.68%,消化类1.50%,抗 病毒类1.47%,其他(补充)0.83%,免疫调节类0.80%,其他类0.57%,利尿类0.34%。 海辰药业所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:固态电池、锂电池、仿 制药、创新药、生物医药等。 截至9月10日,海辰药业股东户数2.18万,较上期增加10.57%;人均流通股3773股,较上期减少9.56%。 2025年1月-6月,海辰药业实现营业收入3.09亿元,同比增长30.46%;归母净利润2915.77万元,同比增 长17.87%。 分红方面,海辰药业A股上市后累计派现1.61亿元。近三年,累计派现1800.00万元。 9月15日,海辰药业盘中下跌2.01%,截至10:48,报66.29元/股,成交4.06亿元,换手率7.33%,总市值 79.55亿元。 资金流向方面,主 ...
奥赛康跌2.03%,成交额8600.23万元,主力资金净流入355.84万元
Xin Lang Cai Jing· 2025-09-15 02:35
9月15日,奥赛康盘中下跌2.03%,截至10:13,报22.24元/股,成交8600.23万元,换手率0.41%,总市值 206.42亿元。 奥赛康所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:医药电商、幽门螺杆概 念、创新药、生物医药、抗癌治癌等。 截至8月20日,奥赛康股东户数1.83万,较上期减少1.26%;人均流通股50724股,较上期增加1.28%。 2025年1月-6月,奥赛康实现营业收入10.07亿元,同比增长9.20%;归母净利润1.60亿元,同比增长 111.64%。 分红方面,奥赛康A股上市后累计派现7.21亿元。近三年,累计派现1.11亿元。 机构持仓方面,截止2025年6月30日,奥赛康十大流通股东中,永赢医药创新智选混合发起A (015915)位居第六大流通股东,持股1168.56万股,为新进股东。鹏华医药科技股票A(001230)位居 第八大流通股东,持股831.18万股,相比上期减少14.91万股。易方达医疗保健行业混合A(110023)位 居第九大流通股东,持股545.12万股,相比上期减少159.47万股。香港中央结算有限公司位居第十大流 通股东,持股46 ...
百济神州涨2.02%,成交额8.29亿元,主力资金净流出552.19万元
Xin Lang Cai Jing· 2025-09-15 02:35
Core Viewpoint - BeiGene's stock has shown significant growth this year, with a year-to-date increase of 99.95%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 15, BeiGene's stock price reached 321.96 CNY per share, with a trading volume of 8.29 billion CNY and a turnover rate of 2.27%, resulting in a total market capitalization of 496.04 billion CNY [1]. - The stock has experienced a 1.25% increase over the last five trading days, a 32.49% increase over the last 20 days, and a 28.58% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading list) once this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300 as of June 30, 2025, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A (China Europe Medical Health Mixed A) with 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选 (Wanjia Youxuan) is the sixth largest shareholder with 3 million shares, a decrease of 500,000 shares [2]. - 新进股东 (new shareholder) 南方中证500ETF (Southern CSI 500 ETF) holds 1.7259 million shares [2].
泽璟制药涨2.12%,成交额5408.06万元,主力资金净流入208.34万元
Xin Lang Zheng Quan· 2025-09-15 01:52
资料显示,苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号,成立日期2009年3月 18日,上市日期2020年1月23日,公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为:药品99.97%,医药中间体及原辅料0.02%,资产租赁0.00%。 9月15日,泽璟制药盘中上涨2.12%,截至09:44,报114.89元/股,成交5408.06万元,换手率0.18%,总 市值304.12亿元。 资金流向方面,主力资金净流入208.34万元,特大单买入367.58万元,占比6.80%,卖出0.00元,占比 0.00%;大单买入638.20万元,占比11.80%,卖出797.44万元,占比14.75%。 泽璟制药今年以来股价涨84.38%,近5个交易日跌2.50%,近20日涨3.50%,近60日涨1.08%。 机构持仓方面,截止2025年6月30日,泽璟制药十大流通股东中,中欧医疗健康混合A(003095)位居 第五大流通股东,持股816.63万股,相比上期增加268.75万股。广发医疗保健股票A(004851)位居第 六大流通股东,持股527.45万股,相比上期减少117.14 ...